Literature DB >> 8314777

Estradiol increases and anti-estrogens antagonize the growth factor-induced activator protein-1 activity in MCF7 breast cancer cells without affecting c-fos and c-jun synthesis.

A Philips1, D Chalbos, H Rochefort.   

Abstract

In estrogen receptor positive human breast cancer cells, anti-estrogens inhibit the mitogenic effect of growth factors in the absence of estrogens. As activator protein-1 (AP-1) activity is one of the first nuclear events following growth factor receptor activation, we studied the effects of estrogens and anti-estrogens on growth factor-induced AP-1 activity using transient transfection of the AP-1-responsive gene (AP-1)4-TK-CAT into MCF7 cells. The growth factor-induced AP-1 response was increased by estradiol and inhibited by anti-estrogens in conditions where growth factor-induced c-fos and c-jun mRNA levels were unchanged by hormone and anti-hormone treatments. The same regulations were obtained when the AP-1 response was directly induced by co-transfection of c-fos and c-jun expression vectors. Co-transfection of the wild-type estrogen receptor HEGO amplified both effects. Inhibition of AP-1 activity by anti-estrogens was unlikely to be explained by the presence of residual estrogens in MCF7 cells. (i) anti-estrogens inhibited AP-1 activity in conditions where they had no effect on basal ERE-mediated activity levels, whereas estradiol was as efficient in stimulating both activities. (ii) The relative efficacy of the two anti-estrogens, OH-tamoxifen and ICI 164,384 in inhibiting these two activities was different; OH-tamoxifen was more efficient in inhibiting ERE-mediated activity, whereas ICI 164,384 was more efficient in trans-repressing AP-1-mediated activity. We conclude that in conditions where c-fos and c-jun syntheses were not affected, the estrogen receptor cooperated with growth factors to stimulate the AP-1 response when activated by estrogens but inhibited AP-1-mediated transcription when occupied by anti-estrogens.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8314777

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  27 in total

Review 1.  Tissue architecture and breast cancer: the role of extracellular matrix and steroid hormones.

Authors:  R K Hansen; M J Bissell
Journal:  Endocr Relat Cancer       Date:  2000-06       Impact factor: 5.678

2.  ER beta inhibits proliferation and invasion of breast cancer cells.

Authors:  G Lazennec; D Bresson; A Lucas; C Chauveau; F Vignon
Journal:  Endocrinology       Date:  2001-09       Impact factor: 4.736

3.  Distinct transcriptional regulation of human large conductance voltage- and calcium-activated K+ channel gene (hSlo1) by activated estrogen receptor alpha and c-Src tyrosine kinase.

Authors:  Shahab M Danesh; Pallob Kundu; Rong Lu; Enrico Stefani; Ligia Toro
Journal:  J Biol Chem       Date:  2011-07-11       Impact factor: 5.157

4.  A transcriptional enhancer required for the differential expression of the human estrogen receptor in breast cancers.

Authors:  Z Tang; I Treilleux; M Brown
Journal:  Mol Cell Biol       Date:  1997-03       Impact factor: 4.272

5.  Effect of estrogen and tamoxifen on the expression pattern of AP-1 factors in MCF-7 cells: role of c-Jun, c-Fos, and Fra-1 in cell cycle regulation.

Authors:  R L Babu; M Naveen Kumar; Rajeshwari H Patil; K S Devaraju; Govindarajan T Ramesh; S Chidananda Sharma
Journal:  Mol Cell Biochem       Date:  2013-04-28       Impact factor: 3.396

6.  Prolactin and estrogen enhance the activity of activating protein 1 in breast cancer cells: role of extracellularly regulated kinase 1/2-mediated signals to c-fos.

Authors:  Jennifer H Gutzman; Sarah E Nikolai; Debra E Rugowski; Jyoti J Watters; Linda A Schuler
Journal:  Mol Endocrinol       Date:  2005-03-03

7.  IQGAP1 binds to estrogen receptor-α and modulates its function.

Authors:  Huseyin H Erdemir; Zhigang Li; David B Sacks
Journal:  J Biol Chem       Date:  2014-02-18       Impact factor: 5.157

8.  Effects of short-term antiestrogen treatment of primary breast cancer on estrogen receptor mRNA and protein expression and on estrogen-regulated genes.

Authors:  R A McClelland; D L Manning; J M Gee; E Anderson; R Clarke; A Howell; M Dowsett; J F Robertson; R W Blamey; A E Wakeling; R I Nicholson
Journal:  Breast Cancer Res Treat       Date:  1996       Impact factor: 4.872

9.  Dynamic, large-scale profiling of transcription factor activity from live cells in 3D culture.

Authors:  Michael S Weiss; Beatriz Peñalver Bernabé; Abigail D Bellis; Linda J Broadbelt; Jacqueline S Jeruss; Lonnie D Shea
Journal:  PLoS One       Date:  2010-11-17       Impact factor: 3.240

Review 10.  Fulvestrant: an oestrogen receptor antagonist with a novel mechanism of action.

Authors:  C K Osborne; A Wakeling; R I Nicholson
Journal:  Br J Cancer       Date:  2004-03       Impact factor: 7.640

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.